Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial
In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis pa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Nutrition and Metabolism |
| Online Access: | http://dx.doi.org/10.1155/2012/510483 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559776401195008 |
|---|---|
| author | Afsoon Emami Naini Mahnaz Moradi Mojgan Mortazavi Asghar Amini Harandi Mehdi Hadizadeh Farhad Shirani Hamed Basir Ghafoori Pardis Emami Naini |
| author_facet | Afsoon Emami Naini Mahnaz Moradi Mojgan Mortazavi Asghar Amini Harandi Mehdi Hadizadeh Farhad Shirani Hamed Basir Ghafoori Pardis Emami Naini |
| author_sort | Afsoon Emami Naini |
| collection | DOAJ |
| description | In patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n=24) or placebo (27 patients) for 16 weeks. At the end of the study, there was a significant decrease in triglyceride (-31.1±38.7 mg/dL, P=0.001) and a significant increase in HDL (3.7±2.8 mg/dL, P<0.001) levels in the carnitine group. Decrease in total cholesterol (−6.6±16.0 mg/dL, P=0.075) and increase in hemoglobin (0.7±1.7 g/dL, P=0.081) concentrations in the carnitine group were not significant. There was no statistically significant changes in LDL in any group (P>0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750±5772 mg, P=0.001) and the placebo group (-2000±4296 mg, P<0.05). No improvement was observed in QOL scores of two groups. In ESRD patients under maintenance hemodialysis, oral L-carnitine supplementation may reduce triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce needed erythropoietin dose without effect on QOL. |
| format | Article |
| id | doaj-art-90addfd477054eb6a9eb57192c50f5ec |
| institution | Kabale University |
| issn | 2090-0724 2090-0732 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Nutrition and Metabolism |
| spelling | doaj-art-90addfd477054eb6a9eb57192c50f5ec2025-02-03T01:29:13ZengWileyJournal of Nutrition and Metabolism2090-07242090-07322012-01-01201210.1155/2012/510483510483Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled TrialAfsoon Emami Naini0Mahnaz Moradi1Mojgan Mortazavi2Asghar Amini Harandi3Mehdi Hadizadeh4Farhad Shirani5Hamed Basir Ghafoori6Pardis Emami Naini7Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranBiochemistry Department, School of Medicine, Jahrom University of Medical Sciences, Jahrom 7414846199, IranIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranDepartment of Emergency Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran 1473115447, IranIsfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan 8168798847, IranIn patients on maintenance hemodialysis several factors reduce the body stored carnitine which could lead to dyslipidemia, anemia, and general health in these patients. We evaluated the effect of oral L-carnitine supplementation on lipid profiles, anemia, and quality of life (QOL) in hemodialysis patients. In a randomized, double-blinded, placebo-controlled trial, end-stage renal disease (ESRD) patients on hemodialysis received either L-carnitine 1 g/d (n=24) or placebo (27 patients) for 16 weeks. At the end of the study, there was a significant decrease in triglyceride (-31.1±38.7 mg/dL, P=0.001) and a significant increase in HDL (3.7±2.8 mg/dL, P<0.001) levels in the carnitine group. Decrease in total cholesterol (−6.6±16.0 mg/dL, P=0.075) and increase in hemoglobin (0.7±1.7 g/dL, P=0.081) concentrations in the carnitine group were not significant. There was no statistically significant changes in LDL in any group (P>0.05). Erythropoietin dose was significantly decreased in both the carnitine (-4750±5772 mg, P=0.001) and the placebo group (-2000±4296 mg, P<0.05). No improvement was observed in QOL scores of two groups. In ESRD patients under maintenance hemodialysis, oral L-carnitine supplementation may reduce triglyceride and cholesterol and increase HDL and hemoglobin and subsequently reduce needed erythropoietin dose without effect on QOL.http://dx.doi.org/10.1155/2012/510483 |
| spellingShingle | Afsoon Emami Naini Mahnaz Moradi Mojgan Mortazavi Asghar Amini Harandi Mehdi Hadizadeh Farhad Shirani Hamed Basir Ghafoori Pardis Emami Naini Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial Journal of Nutrition and Metabolism |
| title | Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial |
| title_full | Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial |
| title_fullStr | Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial |
| title_full_unstemmed | Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial |
| title_short | Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled Trial |
| title_sort | effects of oral l carnitine supplementation on lipid profile anemia and quality of life in chronic renal disease patients under hemodialysis a randomized double blinded placebo controlled trial |
| url | http://dx.doi.org/10.1155/2012/510483 |
| work_keys_str_mv | AT afsoonemaminaini effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT mahnazmoradi effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT mojganmortazavi effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT asgharaminiharandi effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT mehdihadizadeh effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT farhadshirani effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT hamedbasirghafoori effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial AT pardisemaminaini effectsoforallcarnitinesupplementationonlipidprofileanemiaandqualityoflifeinchronicrenaldiseasepatientsunderhemodialysisarandomizeddoubleblindedplacebocontrolledtrial |